![Alliance News](https://static.lse.co.uk/images/news-logos/alliance-news-logo.png)
TRADING UPDATES: Baron Oil boosts P2478 stake amid Upland farmout pact
TRADING UPDATES: Baron Oil boosts P2478 stake amid Upland farmout pact
Read moreFri, 02nd Jul 2021 10:02
TRADING UPDATES: Baron Oil boosts P2478 stake amid Upland farmout pact
Read moreTRADING UPDATES: Strong annual results from Springfield, Fiske
Read moreIN BRIEF: Diurnal's Efmody adrenal treatment launches in UK
Read moreUK earnings, trading statements calendar - next 7 days
Read moreTRADING UPDATES: Power Metal hits "bullseye"; Instem makes acquisition
Read moreTRADING UPDATES: United Oil & Gas in North Sea sale; Trifast confident
Read more(Sharecast News) - Specialty pharmaceutical company Diurnal announced on Monday that the US Food and Drug Administration (FDA) has agreed a special protocol assessment (SPA) for 'Chronocort', or modified-release hydrocortisone, for the design, endpoints and statistical analysis approach of a pivotal study of the product, for the treatment for congenital adrenal hyperplasia (CAH).
Read moreDiurnal gets UK approval for Efmody drug following EU authorisation
Read moreTRADING UPDATES: Gaming Realms BetMGM deal; Argo bitcoin-backed loan
Read moreTRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets
Read moreTRADING UPDATES: Odyssean IT swings to profit; BMO Cap ups dividend
Read moreIN BRIEF: Diurnal extends Citrine licensing deal for Efmody in China
Read moreIN BRIEF: Diurnal gets another patent for adrenal insufficiency asset
Read more(Sharecast News) - Hormonal disease-focussed speciality pharmaceutical company Diurnal Group announced the grant of a patent for 'Alkindi', or hydrocortisone granules in capsules for opening, by the European Patent Office on Friday.
Read more